Check-Cap Announces Receipt Of Nasdaq Minimum Bid Price Notification
Check-Cap Announces Receipt Of Nasdaq Minimum Bid Price Notification
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period.
If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Check-Cap's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "CHEK".
Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced that the Company received a letter from the Nasdaq Listing Qualifications (the "Letter"), indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
納斯達克(以下簡稱：CHEKZ)是一家推進C-SCAN®開發的臨牀期醫療診斷公司，C-SCAN®是第一種也是唯一一種在息肉可能轉化為結直腸癌之前檢測出息肉的方便患者、免準備的篩查測試。Check-Cap Ltd.(以下簡稱“Check-Cap”)今天宣佈，公司收到了納斯達克上市資格委員會的一封函件(以下簡稱“函件”)，表明公司沒有遵守上市規則中規定的繼續上市的最低出價要求。這要求上市證券維持每股1.00美元的最低買入價。
Further, the Rules also provide the Company a compliance period of 180 calendar days to regain compliance. According to the Letter, the Company has from December 23, 2021, or until June 21, 2022, to regain compliance with the minimum bid price requirement. The Company can regain compliance, if at any time during this 180 day period, the closing bid price of its ordinary shares is at least $1 for a minimum of ten consecutive business days, in which case the Company will be provided with a written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance after the initial 180-day period, the Company may then be eligible for an additional time if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period.
此外，規則還為公司提供了180個歷日的合規期，以重新獲得合規。根據這封信，該公司必須在2021年12月23日或2022年6月21日之前重新遵守最低投標價格要求。如果在這180天期間的任何時間，其普通股的收盤價在至少連續十個工作日內至少為1美元，本公司可以重新獲得合規，在這種情況下，本公司將獲得合規的書面確認，這一事項將被了結。如果本公司在最初的180天期限後仍未恢復合規，如果本公司符合公開持股市值繼續上市的要求以及納斯達克資本市場的所有其他初始上市標準(投標價格要求除外)，則本公司可能有資格獲得額外的合規時間，並將需要在第二合規期限內提供書面通知，表明其打算彌補不足之處。
If the Company cannot demonstrate compliance by the end of the 180-day period, the Nasdaq's staff will notify the Company that its ordinary shares are subject to delisting.
如果公司在180天期限結束前仍不能證明其遵守規定，納斯達克的工作人員將通知公司其普通股將被摘牌。
The Letter has no immediate effect on the Company's Nasdaq listing or the trading of its ordinary shares, and during the grace period, as may be extended, Check-Cap's ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol "CHEK".
該函件對本公司的納斯達克上市或其普通股的交易並無即時影響，而在寬限期內(可予延長)，Check-Cap的普通股將繼續以“CHEK”的編號在納斯達克資本市場買賣。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧